Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098761 · ClinicalTrials.gov registry record · Phase 1
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00098761 is a Phase 1 study that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 42 participants.
The verdict
NCT00098761, a Phase 1 study, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in treating young patients with recurrent, progressive, or refractory primary brain tumors.
Interventions
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098761
The ClinicalTrials.gov registry entry for NCT00098761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laromustine is the first listed.
NCT00098761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098761 about?
NCT00098761 is a clinical study titled "VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors". RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in treating young patients with recurrent, progressive, or refractory p...
What is the current status of trial NCT00098761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2005-02. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00098761?
The interventions under investigation include: laromustine (DRUG).
Who is sponsoring clinical trial NCT00098761?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.